open access

Vol 8, No 3 (2007): Practical Diabetology
Review articles (submitted)
Published online: 2007-03-22
Get Citation

11beta-hydroxysteroid dehydrogenase type 1 inhibitor: a novel therapeutic target in the metabolic syndrome

Magdalena Szopa, Małgorzata Wamil
Diabetologia Praktyczna 2007;8(3):77-83.

open access

Vol 8, No 3 (2007): Practical Diabetology
Review articles (submitted)
Published online: 2007-03-22

Abstract

The common metabolic syndrome phenotypically resembles the rare disorder Cushing’s syndrome. However, plasma cortisol level is within normal range. 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) locally controls the availability of an active form of glucocorticoid (cortisol and corticosterone) for glucocorticoid receptor. Recent studies reported that obesity in humans and rodents correlates with enhanced activity of 11beta-HSD1 selectively in adipose tissue. 11beta-HSD1 - dependent glucocorticoid amplification in the fat tissue may explain the Cushing’s syndrome/metabolic syndrome paradox. The evidence of an altered intracellular glucocorticoid metabolism in the pathogenesis of the murine obesity with associated metabolic syndrome underpins the importance of selective 11beta-HSD1 inhibition as a novel target for drug development. Multiple pharmaceutical companies are searching intensively for the 11beta-HSD1 inhibitor with the intention to create drugs that treat disorders such as diabetes type 2, dyslipidemia, visceral obesity, atherosclerosis. Here we review the role of 11beta-HSD1 in the metabolic syndrome and discuss the impact of selective 11beta-HSD1 inhibition.

Abstract

The common metabolic syndrome phenotypically resembles the rare disorder Cushing’s syndrome. However, plasma cortisol level is within normal range. 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) locally controls the availability of an active form of glucocorticoid (cortisol and corticosterone) for glucocorticoid receptor. Recent studies reported that obesity in humans and rodents correlates with enhanced activity of 11beta-HSD1 selectively in adipose tissue. 11beta-HSD1 - dependent glucocorticoid amplification in the fat tissue may explain the Cushing’s syndrome/metabolic syndrome paradox. The evidence of an altered intracellular glucocorticoid metabolism in the pathogenesis of the murine obesity with associated metabolic syndrome underpins the importance of selective 11beta-HSD1 inhibition as a novel target for drug development. Multiple pharmaceutical companies are searching intensively for the 11beta-HSD1 inhibitor with the intention to create drugs that treat disorders such as diabetes type 2, dyslipidemia, visceral obesity, atherosclerosis. Here we review the role of 11beta-HSD1 in the metabolic syndrome and discuss the impact of selective 11beta-HSD1 inhibition.
Get Citation

Keywords

metabolic syndrome; obesity; glucocorticoids

About this article
Title

11beta-hydroxysteroid dehydrogenase type 1 inhibitor: a novel therapeutic target in the metabolic syndrome

Journal

Clinical Diabetology

Issue

Vol 8, No 3 (2007): Practical Diabetology

Pages

77-83

Published online

2007-03-22

Bibliographic record

Diabetologia Praktyczna 2007;8(3):77-83.

Keywords

metabolic syndrome
obesity
glucocorticoids

Authors

Magdalena Szopa
Małgorzata Wamil

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl